We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Financial Strength Remains a Key Advantage for GMED
Read MoreHide Full Article
Key Takeaways
GMED ended Q1 2026 debt-free with about $560.9M cash and $68.9M in short-term marketable securities.
Globus Medical generated $202.4M in Q1 operating cash flow, supporting growth investments.
GMED had $390M left under its share repurchase authorization as of March 31, 2026.
Globus Medical (GMED - Free Report) maintains a strong balance sheet and liquidity position, providing significant financial flexibility to execute its growth strategy. As of the end of the first quarter of 2026, the company held approximately $560.9 million in cash and $68.9 million in short-term marketable securities.
GMED remains debt-free, preserving its ability to invest in research and development, expand its sales force and enhance manufacturing capacity without relying on external financing. The absence of debt also lowers financial risk and eliminates interest expense obligations, enabling management to direct capital toward higher-return growth initiatives.
The company's liquidity position is also being strengthened through internally generated cash flow. During the first quarter, it generated $202.4 million in operating cash flow, reflecting the strong profitability.
The company had $390 million remaining under its share repurchase authorization as of March 31, 2026, providing additional flexibility to return capital to shareholders while helping offset share dilution.
Globus Medical's debt-free balance sheet, nearly $630 million in highly liquid assets and robust operating cash flow position the company well to execute its growth strategy. These financial strengths could serve as important drivers of future market-share gains and margin expansion.
Peer Update
Zimmer Biomet (ZBH - Free Report) ended first-quarter 2026 with cash and cash equivalents of $424.2 million. Debt remained elevated, with total debt of $7.47 billion and net debt of $7.05 billion. The current portion of long-term debt increased to $1.18 billion, reflecting upcoming maturities.
ZBH continued returning capital to shareholders through $250 million of share repurchases during the quarter, a move that may reduce near-term balance-sheet flexibility as the company funds integration efforts and commercial investments. At the end of the first quarter, Zimmer Biomet's debt-to-capital ratio stood at a moderately elevated 37.1%.
Teleflex (TFX - Free Report) exited the first quarter of 2026 with cash and cash equivalents of $309.4 million. TFX’s short-term debt was $103 million, much lower than the cash level. However, long-term borrowings in the quarter were $2.51 billion. Teleflex’s debt-to-capital ratio is 45.9% for the first quarter, implying a relatively high leverage profile that could limit financial flexibility.
GMED’s Stock Price Performance
Over the past year, Tempus’ shares have surged 30.7%, outperforming the industry’s 6.5% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.21X compared with the industry median of 4.52X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, Tempus AI's EPS estimate for 2026 has moved north to $4.74.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Financial Strength Remains a Key Advantage for GMED
Key Takeaways
Globus Medical (GMED - Free Report) maintains a strong balance sheet and liquidity position, providing significant financial flexibility to execute its growth strategy. As of the end of the first quarter of 2026, the company held approximately $560.9 million in cash and $68.9 million in short-term marketable securities.
GMED remains debt-free, preserving its ability to invest in research and development, expand its sales force and enhance manufacturing capacity without relying on external financing. The absence of debt also lowers financial risk and eliminates interest expense obligations, enabling management to direct capital toward higher-return growth initiatives.
The company's liquidity position is also being strengthened through internally generated cash flow. During the first quarter, it generated $202.4 million in operating cash flow, reflecting the strong profitability.
The company had $390 million remaining under its share repurchase authorization as of March 31, 2026, providing additional flexibility to return capital to shareholders while helping offset share dilution.
Globus Medical's debt-free balance sheet, nearly $630 million in highly liquid assets and robust operating cash flow position the company well to execute its growth strategy. These financial strengths could serve as important drivers of future market-share gains and margin expansion.
Peer Update
Zimmer Biomet (ZBH - Free Report) ended first-quarter 2026 with cash and cash equivalents of $424.2 million. Debt remained elevated, with total debt of $7.47 billion and net debt of $7.05 billion. The current portion of long-term debt increased to $1.18 billion, reflecting upcoming maturities.
ZBH continued returning capital to shareholders through $250 million of share repurchases during the quarter, a move that may reduce near-term balance-sheet flexibility as the company funds integration efforts and commercial investments. At the end of the first quarter, Zimmer Biomet's debt-to-capital ratio stood at a moderately elevated 37.1%.
Teleflex (TFX - Free Report) exited the first quarter of 2026 with cash and cash equivalents of $309.4 million. TFX’s short-term debt was $103 million, much lower than the cash level. However, long-term borrowings in the quarter were $2.51 billion. Teleflex’s debt-to-capital ratio is 45.9% for the first quarter, implying a relatively high leverage profile that could limit financial flexibility.
GMED’s Stock Price Performance
Over the past year, Tempus’ shares have surged 30.7%, outperforming the industry’s 6.5% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.21X compared with the industry median of 4.52X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, Tempus AI's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.